-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Gxn239sq1FKtUnbOPbyDl2vmgeM36R16jyyHLZs6/MvG99gXmXKpoY3GA3m+Q8zt
 EUxAcRWSYCOEjx5l+Bbq0g==

<SEC-DOCUMENT>0000950123-10-004904.txt : 20100125
<SEC-HEADER>0000950123-10-004904.hdr.sgml : 20100125
<ACCEPTANCE-DATETIME>20100125163900
ACCESSION NUMBER:		0000950123-10-004904
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20100125
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100125
DATE AS OF CHANGE:		20100125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		10545134

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c94965e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): January 25, 2010</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, New Jersey<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>ITEM 8.01 Other Events.</B>


<P align="left" style="font-size: 10pt; text-indent: 4%">On January&nbsp;25, 2010, Cyclacel Pharmaceuticals, Inc. (the &#147;<B>Company</B>&#148;) completed the sale of 2,350,000 units in its
previously disclosed &#147;registered direct&#148; offering (the &#147;<B>Offering</B>&#148;) to certain institutional investors. Each unit
(&#147;<B>Unit</B>&#148;) was sold at a purchase price of $2.50 per Unit and consists of one share of the Company&#146;s common stock, par
value $0.001 per share (the &#147;<B>Common Stock</B>&#148;), and one warrant to purchase 0.30 of one share of Common Stock (each, a
&#147;<B>Warrant</B>,&#148; and collectively, the &#147;<B>Warrants</B>&#148;). The Warrants have a five-year term from the date of issuance, are
exercisable beginning six months from the date of issuance and will be exercisable at an exercise price of $2.85 per
share of Common Stock.


<P align="left" style="font-size: 10pt; text-indent: 4%">ROTH Capital Partners, LLC acted as the placement agent for the Offering (the &#147;<B>Placement Agent</B>&#148;). Merriman Curhan
Ford served as financial advisor.&nbsp;


<P align="left" style="font-size: 10pt; text-indent: 4%">The net proceeds to the Company from the sale of the Units, after deducting for the Placement Agent&#146;s fees and
offering expenses, is approximately $5.4&nbsp;million. Following the issuance of the 2,350,000 shares, the Company has
31,398,820 shares of Common Stock issued and outstanding.


<P align="left" style="font-size: 10pt; text-indent: 4%">On January&nbsp;25, 2010, the Company issued a press release announcing the closing of the Offering described above
under item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached hereto as Exhibits 99.1
and incorporated herein by this reference.


<P align="left" style="font-size: 10pt; text-indent: 4%">Neither the filing of the press release as an exhibit to this Current Report on Form 8-K nor the inclusion in the
press release of a reference to our internet address shall, under any circumstances, be deemed to incorporate the
information available at our internet address into this Current Report on Form 8-K. The information available at our
internet address is not part of this Current Report on Form 8-K or any other report filed by us with the SEC.


<P align="left" style="font-size: 10pt"><B>ITEM 9.01 &nbsp; Financial Statements and Exhibits.</B>


<P align="left" style="font-size: 10pt">(d)&nbsp; &nbsp;Exhibits:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">No.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><BR>99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><BR>Press Release dated January&nbsp;25, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">





<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.



<P align="left" style="margin-left:46%; font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>


<P align="left" style="font-size: 10pt">Dated: January&nbsp;25, 2010



<P align="left" style="margin-left:46%; font-size: 10pt">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Paul McBarron&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<DIV align="left" style="margin-left:52%; font-size: 10pt">Name:&nbsp;&nbsp;&nbsp;Paul McBarron<BR>
Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Vice President &#151; Finance,
</DIV>

<DIV align="left" style="margin-left:58%; font-size: 10pt">Chief Financial Officer and Chief <BR>Operating Officer
</DIV>


<P align="left" style="font-size: 10pt">

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Exhibit&nbsp;Index:</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">No.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><BR>99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><BR>Press Release dated January&nbsp;25, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c94965exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">

<P align="right" style="font-size: 10pt"><B>Exhibit 99.1</B>

<P align="left" style="font-size: 10pt"><IMG src="c94965p9496501.gif" alt="(LOGO)">

<P align="right" style="font-size: 10pt; margin-top: -33pt">Cyclacel Pharmaceuticals, Inc.

<P align="right" style="font-size: 10pt">&nbsp;

<P align="right" style="font-size: 10pt"><IMG src="c94965p9496502.gif" alt="(PRESS RELEASE)">

<P align="center" style="font-size: 10pt"><B>CYCLACEL COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING</B>



<P align="left" style="font-size: 10pt"><B>Berkeley Heights, NJ, January&nbsp;25, 2010 </B>&#150; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#147;Cyclacel&#148; or the
&#147;Company&#148;) announced today that it completed its previously announced registered direct offering through the sale of
shares of its common stock and warrants for gross proceeds of $5.9&nbsp;million, before deducting placement agent fees and
offering expenses, in a registered direct offering with select institutional investors. The offer included the sale
and issuance of 2.35&nbsp;million units, each unit consisting of one share of the Company&#146;s common stock and a warrant to
purchase 0.25 shares of common stock, at a purchase price of $2.50 per unit. The warrants, which represent the right
to acquire an aggregate of 705,000 shares of common stock at an exercise price of $2.85 per share, have a five-year
term from the date of issuance and are exercisable beginning six months after the date of issuance.


<P align="left" style="font-size: 10pt">The units were offered and sold pursuant to a prospectus supplement dated January&nbsp;21, 2010 and an accompanying
prospectus dated February&nbsp;12, 2007, pursuant to the Company&#146;s effective shelf registration statement previously filed
with the Securities and Exchange Commission.


<P align="left" style="font-size: 10pt">Roth Capital Partners, LLC served as the sole placement agent for the offering. Merriman Curhan Ford served as
financial advisor.


<P align="left" style="font-size: 10pt">This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such jurisdiction. Any offer will be made only by means
of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of
the final prospectus supplement together with the accompanying prospectus can be obtained at the SEC&#146;s website at
<U>http://www.sec.gov</U> or from Roth Capital Partners, LLC at 24 Corporate Plaza, Newport Beach, CA 92660.


<P align="left" style="font-size: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel,
mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are
in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for
the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans
to submit a Special Protocol Assessment (SPA)&nbsp;request for a pivotal study with sapacitabine during the first quarter of
2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the
treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an
Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel&#146;s ALIGN
Pharmaceuticals subsidiary markets directly in the U.S. Xclair&#174; Cream for radiation dermatitis, Numoisyn&#174; Liquid and
Numoisyn&#174; Lozenges for xerostomia. Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in
hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug
candidates. Please visit <U>www.cyclacel.com</U> for additional information.



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%"></TD>
    <TD width="47%"></TD>
    <TD width="50%"></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD align="center" valign="top"></TD>
    <TD align="right" valign="top"></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" colspan="3"><FONT style="font-family: Wingdings">&#254;</FONT> 200 Connell Drive, Suite&nbsp;1500, Berkeley Heights, NJ&nbsp; 07922 USA
 T: &#043;1 (908)&nbsp;517 7330 F: &#043;1 (866)&nbsp;271 3466</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-family: Wingdings">&#111;</FONT> Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel &#043;44 1382 206 062 Fax &#043;44 1382 206 067</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center" style="font-size: 10pt"><U>www.cyclacel.com</U> &#150; <U>info@cyclacel.com</U>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>Risk factors</B>


<P align="left" style="font-size: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results or from any future results expressed or implied by
such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the
efficacy, safety, and intended utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical
trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to
differ materially include the risk that product candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will
not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital
requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development
and commercialization of product candidates. You are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148;
&#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148;
&#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable words to be
uncertain and forward-looking. These factors and others are more fully discussed under &#147;Risk Factors&#148; in the Annual
Report on Form 10-K for the year ended December&nbsp;31, 2008, as supplemented by&nbsp;the interim quarterly reports, filed with
the SEC.


<P align="left" style="font-size: 10pt"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Investors/Media:
<BR>
Corey Sohmer, (908)&nbsp;517-7330
<BR>
<U>csohmer@cyclacel.com</U>


<P align="left" style="font-size: 10pt">&#169; Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&#174; are trademarks
of Cyclacel Pharmaceuticals, Inc. Numoisyn&#174; and Xclair&#174; are trademarks of Sinclair Pharma plc.


<P align="left" style="font-size: 10pt">SOURCE: Cyclacel Pharmaceuticals, Inc.


<P align="center" style="font-size: 10pt">2

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c94965p9496501.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c94965p9496501.gif
M1TE&.#EAVP!/`/<```````"$S@"$U@",U@"4U@@("`B4UA`0$!"4UA"4WA"<
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M[^_W_^____?W]_?______P``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#;`$\`AP````"$S@"$U@",
MU@"4U@@("`B4UA`0$!"4UA"4WA"<UA"<WA@8&!B<UAB<WB$A(2&<WB&EWBDI
M*2F<WBFEWC$Q,3&EWC&MWCDY.3FEWCFMWD)"0D*MWD*MYTI*2DJMYTJUYU)2
M4E*UYUI:6EJUYUJ]YV-C8V.]YVMK:VN]YVO&YW-S<W/&YW/&[WM[>WO&[X2$
MA(3&[X3.[XR,C(S.[Y24E)3.[Y36[YR<G)S6[Z6EI:76[Z76]Z7>[Z7>]ZVM
MK:W>][6UM;7>][7G][V]O;W>][WG]\;&QL;G]\[.SL[G]\[O]];6UM;O]];O
M_][>WM[O]][O_][W_^?GY^?W_^_O[^_W_^____?W]_?______P``````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````C^`+4('$BP
MH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$F28Q,C.UAPL&#`
M`(*6#CBHV+$#2D0L-Q7BM+CS8<^>.3\"]?B3(94B+#(T&,"40,NG3YD.:)"A
MA!";!8<BU*J58%>(7Q.&]5FR[,(F+"8,(##@Z4NW4-^R9=H@!9**8\>*':C7
M8%^&?_D*%EB4\."L9@DBX8!@+=3';Q^[A,K6`(<>@#L6)FMXXN:&@1-/5,+!
M0%NXD@D$D`PW,E,-0DB&]DOQ,UBA(C]7:6$:=<L!`1PC4*``P4O5P%F_74L"
MJ\2PLQ%[QAB=.DDA%E8_GDN@PPD5-I3^((%B!8H2(S92G+#`EH#3N+\;Y-CK
M5;J6Z+8Y\]2_N;]H@BST!A5P#8"PPQ)5-)0%$CEPX$``[VTW0`H);G51?@YA
M"-IAF7%4W416G`"A:P1D8`,5!55AA1`QL.!B"BS0($2%`D%!`P5,^3:`!4UX
M:-UTG07UWWX"-:%!6\L-P($061"D1`XG--!`8\!)U58#$*10TT`['!GA<A,X
MM]"'&=9V84AD3@2%!:?]9L$.30I4!1`<*-!4A*S-U<"2.]VP%'P#R*"3A4%N
M6.AM1(YYF'^'UO?1FFVN12%!-[#9)FN8MI?!?%I`<<*E!@20`D@:=G@?D*>:
M2FI'5AP950/^L7%Y`80#,@6A5!#>BJ=I!&A0A$`Y-!85#3Z>^1R'AN(F4@J7
M9M"CG,Q&&H`"%G`@(Q+88FL$#2LA0&M++ZW%0I--9%`E!TU6P02-M.6&ZK&K
MEL2"=J:A.Y`2.$9%@`4T[-`0$C2P]&VXSFJ1Q0XQ^*M%#14`4,$/B@8Y6ZF#
MFFDJHZEF7!82$0:@`D%"V/F;`2+`.1`4._2@$@<LGY###DH,9`0)"M#;6`-W
M$10$`#P#4``1&U%,G\;)_I6FJAJU>MH`)!"T0V^J7:"P%E3LP`$$P'%G*P$(
M:,`"5D5P4-EO&<0ID`D]\XR"L7@)B1^:]F7TPFJ-V2M0#XTAX!3^#7%"P<)2
M[AG07E.U&D!"K#N(+/@`8J*=]MK_O6VQLB,UH;=I#3BGQ.53_2J0#4NUE;4!
M5+'<`%L0OM=6<UHHH<&M)Q2$0]H`Z!!QQJ$)W>Z[0V.L>T>?@IMSIZ?7:T6-
M'#C6E@4R%+$$%'TO(412WJK>`&99Q,`!"\=/D<04`KG````,S'`0NX@2?;';
MR1+ET1)1L4"0V*%R<+P62``^+0O#*S2]XA"2'T&(,+X''$$@4_@!^B8G&V0A
MK5@@$9'@,D`0&[0E`""(TPX:XY03.`=EW()``R@P`0[(8`?W\Q13PA4K@8R/
M9Q)`R`+AUJB#I.EH0S((%)Y"@*DU(73^81(($O0VE18J(4I;RUJ5ZO(L(^AO
M:E@X0,\.,)`9VG!1.6Q?[[`H,='(X()-&PBSG&*$(H6.`U*H40J0XQ0'6"`#
M%#B.5`R@`IM$002&N]_9>K8"=W6Q:&6JX>[8YD",5"$#@8M9D?06`&()Y$@#
M.$&%A!`Z!)!@!U2@D16D8`,.+"4X$\`,U01"A!E`3`LS"$$-'&)%0MUN<CB$
MH$&JT$J'+,$ID21(M#0PD'D1``0#N8%I$,""9QD,"E2``HV.R"L#3"T)/;-=
M%@G)N[),00=32&":YM:2J4$!`DZ)51-,,X$*W0`X'%!D%=(C,`)0@`,Q:&)V
M`A`[@<R.9WW^G&;D!CF2*NC@!T0XPC\K(K8=$20'Z!Q("0*`@)P)`3@GB),,
M&K.::GVR+1XT6`I8)Y`G/```!P!:26*IST0Q`:`C<$$27$`1*TP@@/-SCS@;
M,RKBY5(+2WB=`EC@O.-!`27)"\`"."60(Z"`"5J80A"0FA`:U;*DOYOF28D0
M`A-@@:4304);"#`\*WC+;C$(0`3N)Z(P;FY"8BJ($3@0@`#D#`L?W4!32VH6
MDDJD"CCX`1.2\`-I2F0';+&`'@$[``%JH0&-%(@22.=3Q'KNBAH5@7-,4(!\
MRHFNF+6F#IYP33+1`$+U%`@+!H``11K!)5@1D<+$5L:X&80)(DW^0D:>H(,5
MA,`#*,`!$[#`!!2L``<)Z2T*@F"0)^#`MKBM01)VDH05K.`)#]&!;XG;$";4
M]K8KJ,&ZBNK<[G87!7Z5K@O`YZB!<-8B(F"*8;60@@!<H)<"*(%`J&``7FIA
M!P&`(FC&1]Z+!,$#M(NF%AH&`-D>!,``@.Y`@A""`/-,FO<\H&L[.L6GZF`#
M#@8`<!>680!@8"`(EG!(*,"U_B4OC.S-KT``JS`*H!@B+K#JA5#0LPV`EP@U
M"($$@`M-`&Q`*SK@V8;OXS@`X%8'I1R!!*099`"(>)`SX%D!:M=4QQ7``RM`
M\@P\\`#S:>&>(7"!F,6<91#[[,D?48W^`SX(@0!P*@L9,(`B26``FPA!SA4C
MS`C\>MF&++#!'C8P0:I`7A<\.$7CD^M``+T!05>1O$U&\U8D```4`-@#"0%T
M")A*D"DHN`8\$RE"&EP`1T]X(C#1XS@'$"LH(.`".V&9:#D`68-,@0%8];-"
M[OGCA52!T@]@EZ$/P.DF>P`H6HEP0W8&@&OZS-0"@8':&`)J`)P2(0`N]:G3
M)#@(T&@)3&EM$Y@FD"Q,0(`<L$$A!Y($I%9A+$^MXO@80*.P_(!GN4["E'-=
MA0+&.]+\U,((C*R%*NS;UE*40+RK?>V#D%K2'1&<W;0P;JX624GE/K<6K&"!
M_BED!5[6"+/^83`T@9!:P0"N0$^8'?+=`7PA3YCRAM'&`(-4>Y74YAEUL?WL
MD=2+(.!NP+.@0&Z#;6KC/`HDJGKB.%$SY`GC"X$6[OTS@C2](<I>B+3I+1!F
M-UP+*P!I?QU8[9T[O.<EIXA[.$`C*2`@<T4B6;DM,)\J)+W6\*9(@X,-D9M3
M&G)F?L#8$_)RL30,\%KXJ-3Y@@'R_:7:%0C!;2<OZ&Q+VJX"P='$JT!B15JA
M`2BVED!(L(3RDJ3!$NC+3QH_9;X3).4.R;KIF?UD:2>XBI1FP.,[O'-20[LC
M)`B`!LRFA>"W5@LBH/4C:\K3NS(DWJB/SA&F3.6"`%CA#2G\J'W^7!`F2)'D
MA,G][@$0YC&+6<%:R/;O.8+0!K"KO<=/`04JU(*:YF"]>9;A*[7P<(E@^`%:
M87G9QS,09UY2Y&4X@1/7UQ,-=@#QQF$`X'0&T7_Y-Q$[0%IZI`6?-34^8'$4
M)U@;%U'VH1<DF!"&!@`X9RH85@$+=()#MFL$J!!1!@`/@`$58(,8@`%2!``[
M9WM\EA`,IQ#J-Q)&,``*(";CI'P%IP`*DP4<T%K],B1,P#,5X'\`D'JO184#
MZ&0*\5$=QC,C,!!'P#.*MA!!F&EH%Q)90`%N1A!9@``3T!,DH(2=)"=?(TL*
M`6B(UQ`8AH4&,7"5QA#:5Q`[4P`X\`3^3+!7BL@$#=A?"`9^"G&&/*=M#P01
M&B``-=5+`_!8&X05<!8KT_,C>$<0'J4V@Z<0?<@N.U&*E7:*J=)DG/:'5Y@0
M]P8`D.A]/`,#M51M$E@0I!:+(/%9(,`N11``,4`0%I")=,(E-_`0Q'<13."%
MN(8#09`$.C`#(_![*_@522"-+D"-`H6-U-5D,!`$/W".?05=3\`S+9<5'Z5R
M`T$$7O@`WQA0/P`#(W!*U;8"Z'B.2&9F`&!*_:@#ZU<1XV8`QB00%]``9K,#
M0C<0)Y")").0YY,#+52!5S0%)K"#`?:"`]%XKG<04S`"U!=@$-9A)"=M!0",
M!7&"3O<$))G^85Y6;0X60P*!8`ZVAQCAA`(P-2L6`*(D$!SP8B2@;D5"`SE`
MD?-E!#)PD0'G$$F``RB``0QP`!4P`C6`?@01`@S0:PIAC290`56)`1Z0E0+Q
M`P?``%6YEFFY2AO``&'XE6JIDTE0`R-`E0R``2.@6_:DEFRYEL<F$"/@EVE9
MF+CF$3(0`$HH$"XU`6;C:E.3!2EPC/=B`T5@`S"S`R_S,NSR@'^T%5@P%$6!
M!>^&.\@2FEQ!FJKY;N^&$ZWYF?=!FA62FJ&9%:MYFPEX'ZQYFZ5IFA9!!2_A
M<1?HDPYI3%D0D>Q"!4C0!%+0!,M9$%;``CZ96=19G0_!`@*`?UK^X$D9&`,3
MD)`Y<$G/>!`'XS(8:9WHB5FNA@`H0A"6\V):D!9BXC<JD`.99!!9``4V<`)W
MF)[^^9\&H0*B8A`YH&(`0@&*=#(IP0(O0Q,YD![2J90WT)Z[LQGUQD6^F:&^
M@Z$;^ID=JJ$<BJ$8$04-@)`&00*E51`YT`".5!`+(@2:*01+,)XX-92>":`X
MFA@W(`"+66Z,09&+\0%.V1!^8R(Y>J34604=$`#-Z*)L57H%834B,",-400I
MD`$9A:1:2E>6@P!*Z80(<'P#<3`B(`(G4!/W67#E8:4DD`'%=!!0D%8?.J<A
MZJ%U"J)VFJ=XNJ=1]1`V$``@>*),BA#^-L("*3"4)\`R'[`]=D&C]V4`1KFE
MDFH6\]*C`V$#EE%+<8HMS^.H-8*B1HEYDSJJ"1%\F5@02Z`4,7"C"!&=5*&4
MI!JK/F(%Z:6=`Y$#$#`!JSH1:#%"1#6*>DJGP7JGPLJGQ'JL@G0152`"`RI#
M-P)Z5]$02K`#&:``%&`#K"JKVEH15L!6'U!+.Z`"#J`!)'`"X1&GZ#H]+!,!
M#L`"0QJEE+FM\GH1\V(!":H^58`$+'`")<`!%&`!`/M.)$`"7_-4T2D`H36O
M"KL^6B!,@?(052`%Z`H]#X$$V3$NR&JLP[JQ&MNQQ5JL(T$:PN=Q'.$I8C6=
M"YNR$F$#C7&0`E"J'X0J`Z:1`FFELC8+$520`J9Q`O=:$4J0`MX"`CU[LT0+
M$4V@LP.@`390L\F:G]K#%"!`LD4[M0]A!0&S%FZZ`T_%("P`3F+5GU0;MA2Q
M!#:@`0[`-1,P`1E0KB=P`FUJ`:%#%3*`!!DHMG9+$4K@`SGP`B?PKP&K`2]P
4`SN`!)YZMX9[N(B;N(J;10$!`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>c94965p9496502.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c94965p9496502.gif
M1TE&.#EAG`(A`.8``).3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYR<G)V=
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M^/GY^?KZ^OO[^_S\_/W]_?[^_O___P``````````````````````````````
M`````````````````````````````````````````````````"'Y!```````
M+`````"<`B$`AI.3DY24E)65E9:6EI>7EYB8F)F9F9J:FIN;FYR<G)V=G9Z>
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M^?KZ^OO[^_S\_/W]_?[^_O___P``````````````````````````````````
M``````````````````````````````````````````````C^`-<('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRH)J3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2(<B3,JTJ5.8!W=&U3DUITFJ
M!)^NK(J3:\VL6`U*'>CS:E>Q6M.J-;ITK=NW/M-D63*DR!0T:W9J64*D2!0R
M>7-^:>*D,),J5M=D,>*7#-4P?)=\>4M&RI$A2K((U$F%L&$Q.:TP>5)FYYDH
MGIL\,4-U"Q,GH,=>82RE=,[.A9LT"0.WM^^O7G\+'ZY&H(P(#1(D<!#B2F";
M:VQ`2)Z@P08ES[\24?"`@8(!)++^U]P1X8#Y&N)GKI&B(4$!`QK&I$^ZILL&
M"`H0*(C`(LQ\J&F(L,`#"BA`@!/_N210"@E$H)E58&#`@`/Y.;!%@B\MF(`"
M/6`84QHW0&"`>3EXR))`(7"G0`('+&$B<3`^U5:,-+XE4`D(:%#%%!\<X`%@
M-ZV1P@$52($%"@@X^*)*:Q3!0`,FZ&"#$4NFM`82"C3P0A$NN!@D&!DD`,(0
M4J91)5!K8.'="UP@,8$!+705X`(4U"`E%V<6)Z0"$CS8%9@+8)`##CR(D>=)
M]5'0@`(G%&<5$0@X$`.7"`:Y1HH4T)###5H<6N.G/\T(ZJA,"81"`AZ<L482
M###@)73^*R"0`6!61)"`#H<VV<`"09`%W1HL(."!F9X6IX0""T3A:UJ*X;>#
M0#$D0($7>:Z1Q@@+9%#&LC0)I,("$_CYI08*B`!6D$,HD($$$ES8E1HI(``"
MM\")H*Y\FY&J+WW![>MOJ&N<VH%\4#B0P!"YQIJ!?U]8@(`,N1:Q:Z_Y?J6&
M"0I04$7%T&W'P+,<RY@%?B6NP8,"$'0*W;79`N:IM^"*"QT8Y)H;<K=JJ(#`
M#AXD`,3+URI@`18WJ[>&O1G@^^_22O7+]-._GNH!7CPLX("R02J\[1,4OOJ5
MQ`VXP`027^3:0Z08^&!H5UH@!X$+SA7+4[,*@,Q"`2&842W^RQ8,D<03:5CZ
M;;C%KD'S`M<A006$%+0+@P$GF-F5#I%F\(-\9]EK@1!*-`'UYV.A!?KH1J.P
MP`4]S`#!`2G@E74"%T#1Q`8-U"`Y=!)#P,`!`QR1*QDH(*L`!\YU!02%*`LA
MMU0C+_#"%3<XD($4N5[K``0(")"!WK\.+O-7-#OPP`$"G%`T5$:(N<80";3[
MLA@8+Z#`!RK_*D(#$"0P``6WD^Y_AD[[GP!-U8`(2"`"&)`!YK*F@`I0`&4(
M>IG$'*`"(@`!3UTY@P\P0*&\Y6H-42#!`QQPM>599600P,`#$)""!:YL!`RH
M``^"D(3`=2]FA3M<!H0`!"><907^!7A6%R:@`(19Q0P\4*$"2*`J^RV@`CL(
M@A$$2,66B*J*5#25`C90A2T8JG"Q\H`/'-``'Q1.8KRB%W#L@S\JO,Q:,C"8
M#4S8E>;=@$$9*)N<L#6K\T%E#=[+8<W4*),U?*$"#%"!E(B8`D>=90L9*&#Q
MZG4O/V*1=%>\I/],A2I5+6\-L=*`&%30/J)U!8T_LR0`!8(Q"+CQ+&LP0G)N
M0,<@C4P!/L`"?EJ@RA.Q+&F$_./@\-3+K="L7,%$'P,B4($)4&`"#Z!`%]XH
M$`%)8)+=.IJZOEA+3<(HD]X$'2<'9D)0RLH,NDP`"ASYM0;4+@M5P"!TFG`#
M)^!``@K^\`#WOO(%&R3!"!UXTA.Z^95;X@H&"G!`$ZJ'K0LX`0M5`!)P!J<$
M+&"AB>#3P`(Z<(4K7/1,`FG!`5``!C"(X0>M4EZ0EH"#)MA``@D(`4:S::\+
M-`$+5I!H.#<9P)TN32`C$``&7&B5$P1@`OZ)P7N(D*LA&"`!"V!``4I0+4`"
M(#\)J``4<K6$`""`10VXP5K2]!WT<&$"!%C8WCQP@`5$U0`#_94)#.#6!#S`
ME/RD0%L78%=W=:L+$1B`\@32!0B`AYV%O-A5#X"`"U#/4AZ@:UV]YE-Q]K2R
M_PJ""W:P3ZH,H04X`(P79N`"'_1//5.`P0QD$`,7]`HG4*#^00I4@(/ZW<0+
M/&`!"F#`A&(J!0PR$)M`CO""%VSL)FGP00Q6&X,7V+8F0U"M#&!``S!4BPPX
M6&X,J.N?KVCA!3.8)DIZ\((<Z)0F3IC!;'7@5YSX0+K;Q2MF/P?.^?[4MS'Q
MU;E^999?Z4EN9$DFO_(EX#_V%S@'SN9^%9R=`BLH+PY>Y8+M>U_141AJ!$6L
MAJ&#DG+6,L+TL=(G.RR54/5D/AXNRX5Y:N$5N_C%,(ZQC.U;WQG;^,8XSK&.
M?5/C'?OXQT`.LI#S>]DA&_G(2$XRC8NLY"8[^<E0WE>/HTSE*EOYRC+B2DFV
MS.4N>_G+8`ZSF,=,YC*;^<Q@%K'%A=',YC:[^<UPCK.<YTSG.I-$S5>!5@A(
MP.<^^_G/@`ZTH`=-Z$(;^M"(3K2B%\WH1COZT9".M*0G3>E*6_K2F,ZTIC?-
MZ4XS.@0Q(#!7?C"#&ICZU*A.M:I7S>I6N_K5L(ZUK&=-ZUK;^M:XSK6N=\WK
M7OOZU\`.MK"'3>QB&_O8MI[!#_"\7SL[^]G0CK:TITWM:LN9V2#&LK:WS>UN
H&]C:X`ZWN,=-[G*;^]SH3K>ZU\WN=KO[W?".M[SG3>]ZVULC`0$`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
